MSMalte Stockebrand

Malte Stockebrand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malte Stockebrand has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Altered oligodendroglial cell development and increased myelination in SCN2A gain-of-function-linked epilepsy

    by Constanza Bravo-Rossainz Baez, Xian Xin, Hang Lyu, Daniil Kirianov, Ying Sun, Erik Späte, Mariapia Grassia, Birgit Engeland, Malte Stockebrand, Konstantin Khodosevich, et al.

    Gain-of-function variants in SCN2A, encoding the voltage-gated sodium channel Na V 1.2, cause developmental and epileptic encephalopathies characterized by seizures, developmental delay, and white matter abnormalities. While Na V 1.2 is known to regulate neuronal excitability, its role in oligodendroglial cells is unclear. Here, we show that Na V 1.2 is expressed in early oligodendrocyte lineage stages. In mice carrying the gain-of-function Scn2a p.A263V variant, oligodendrocyte precursor cells displayed similar Na V 1.2 expression, but altered electrophysiological properties and calcium signaling. Single-cell transcriptomics revealed stage-specific changes in oligodendroglial maturation during early postnatal development, associated with lower variability and slightly faster conduction velocities. In adult mutant mice, gray matter myelination was increased without changes in oligodendrocyte numbers or myelin structure. Since Na V 1.2 was absent from mature oligodendrocytes, the enhanced myelination likely reflects an activity-dependent adaptation to altered neuronal network activity rather than a primary myelinopathy. These findings identify a glial contribution to SCN2A -related disease mechanisms and underscore the need to consider neuron–glia interactions when developing targeted therapies for epilepsy.

  • Open Access

    Early postnatal CA3 hyperexcitability drives hippocampal development and epileptogenesis in SCN2A developmental and epileptic encephalopathy

    by Yana Reva, Katharina Ulrich, Xian Xin, Yuanyuan Liu, Michaela Barboni, Daniil Kirianov, Nima Mojtahedi, Sarah Schoeb, Hanna Oelßner, Daria Savitska, et al.

    Developmental and epileptic encephalopathies caused by pathogenic variants in SCN2A ( SCN2A -DEE), encoding the voltage-gated sodium channel Na v 1.2, present with early-life seizures, developmental delay, and increased mortality. Using a novel Scn2a p.A263V gain-of-function (GOF) mouse model, we demonstrate gene-dose and background-dependent phenotypes ranging from self-limited neonatal seizures to chronic epilepsy with high mortality. In vivo electrophysiology revealed hippocampal seizures as early as postnatal day 2.5, with CA3-driven gamma oscillations preceding seizure onset. CA3 and CA1 pyramidal neurons exhibited transient hyperexcitability during early postnatal development, resolving by P24-30. Single-cell RNA sequencing uncovered gene dose-dependent accelerated maturation of hippocampal networks, peaking at P7, alongside widespread transcriptional changes in excitatory and inhibitory neurons. In adulthood, persistent hippocampal network alterations emerged, marked by reduced mid-gamma oscillations and theta-gamma coupling. Our findings establish hippocampal CA3 hyperexcitability as an early driver of epileptogenesis in SCN2A -DEE and highlight it as a potential therapeutic target to mitigate disease progression.


  • Open Access

    Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy

    by Andrea Merseburg, Jacquelin Kasemir, Eric W Buss, Felix Leroy, Tobias Bock, Alessandro Porro, Anastasia Barnett, Simon E Tröder, Birgit Engeland, Malte Stockebrand, et al.

    De novo mutations in voltage- and ligand-gated channels have been associated with an increasing number of cases of developmental and epileptic encephalopathies, which often fail to respond to classic antiseizure medications. Here, we examine two knock-in mouse models replicating de novo sequence variations in the human HCN1 voltage-gated channel gene, p.G391D and p.M153I (Hcn1G380D/+ and Hcn1M142I/+ in mouse), associated with severe drug-resistant neonatal- and childhood-onset epilepsy, respectively. Heterozygous mice from both lines displayed spontaneous generalized tonic–clonic seizures. Animals replicating the p.G391D variant had an overall more severe phenotype, with pronounced alterations in the levels and distribution of HCN1 protein, including disrupted targeting to the axon terminals of basket cell interneurons. In line with clinical reports from patients with pathogenic HCN1 sequence variations, administration of the antiepileptic Na+ channel antagonists lamotrigine and phenytoin resulted in the paradoxical induction of seizures in both mouse lines, consistent with an impairment in inhibitory neuron function. We also show that these variants can render HCN1 channels unresponsive to classic antagonists, indicating the need to screen mutated channels to identify novel compounds with diverse mechanism of action. Our results underscore the necessity of tailoring effective therapies for specific channel gene variants, and how strongly validated animal models may provide an invaluable tool toward reaching this objective.


  • Developmental HCN channelopathy results in decreased neural progenitor proliferation and microcephaly in mice

    by Anna Katharina Schlusche, Sabine Ulrike Vay, Niklas Kleinenkuhnen, Steffi Sandke, Rafael Campos-Martín, Marta Florio, Wieland Huttner, Achim Tresch, Jochen Roeper, Maria Adele Rueger, et al.

    Significance: Impaired cell cycle regulation of neural stem and progenitor cells can affect cortical development and cause microcephaly. During cell cycle progression, the cellular membrane potential changes through ion channel activity and tends to be more depolarized in proliferating cells. Hyperpolarization-activated cyclic nucleotide-gated cation (HCN) channels, which mediate a depolarizing current in neurons and cardiac cells, are linked to neurodevelopmental diseases and also contribute to the control of cell cycle progression and proliferation of neuronal precursor cells. In this study, HCN channel deficiency during embryonic brain development resulted in marked microcephaly of mice with impaired HCN channel function in dorsal forebrain progenitors. The findings suggest that HCN channel subunits are part of a general mechanism influencing cortical development in mammals.


  • Open Access

    Seizures, behavioral deficits and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy

    by Andrea Merseburg, Jacquelin Kasemir, Eric W. Buss, Felix Leroy, Tobias Bock, Alessandro Porro, Anastasia Barnett, Simon E. Tröder, Birgit Engeland, Malte Stockebrand, et al.

    De novo mutations in voltage- and ligand-gated channels have been associated with an increasing number of cases of developmental and epileptic encephalopathies, which often fail to respond to classic antiseizure medications. Here, we examine two knock-in mouse models replicating de novo mutations in the HCN1 voltage-gated channel gene, p.G391D and p.M153I ( Hcn1 G380D/+ and Hcn1 M142I/+ in mouse), associated with severe drug-resistant neonatal- and childhood-onset epilepsy, respectively. Heterozygous mice from both lines displayed spontaneous generalized tonic-clonic seizures. Hcn1 G380D/+ animals had an overall more severe phenotype, with pronounced alterations in the levels and distribution of HCN1 protein, including disrupted targeting to the axon terminals of basket cell interneurons. In line with clinical reports from HCN1 patients, administration of the antiepileptic Na + channel antagonists lamotrigine and phenytoin resulted in the paradoxical induction of seizures in both lines, consistent with an effect to further impair inhibitory neuron function. We also show that these variants can render HCN1 channels unresponsive to classic antagonists, indicating the need to screen mutated channels to identify novel compounds with diverse mechanism of action. Our results underscore the need to tailor effective therapies for specific channel gene variants, and how strongly validated animal models may provide an invaluable tool towards reaching this objective.


  • Subcellular localisation of human inositol 1,4,5-trisphosphate 3-kinase C: species-specific use of alternative export sites for nucleo-cytoplasmic shuttling indicates divergent roles of the catalytic and N-terminal domains

    by Marcus M. Nalaskowski, Sabine Windhorst, Malte C. Stockebrand, Georg W. Mayr

    The three isoforms of human Ins(1,4,5)P3 3-kinase (IP3K) show remarkable differences in their intracellular targeting. Whereas predominant targeting to the cytoskeleton and endoplasmic reticulum has been shown for IP3K-A and IP3K-B, rat IP3K-C shuttles actively between the nucleus and cytoplasm. In the present study we examined the expression and intracellular localisation of endogenous IP3K-C in different mammalian cell lines using an isoform-specific antibody. In addition, human IP3K-C, showing remarkable differences to its rat homologue in the N-terminal targeting domain, was tagged with EGFP and used to examine active transport mechanisms into and out of the nucleus. We found both a nuclear import activity residing in its N-terminal domain and a nuclear export activity sensitive to treatment with leptomycin B. Different from the rat isoform, an exportin 1-dependent nuclear export site of the human enzyme resides outside the N-terminal targeting domain in the catalytic enzyme domain. A phylogenetic survey of vertebrate IP3K sequences indicates that in each of the three isoforms a nuclear export signal has evolved in the catalytic domain either de novo (IP3K-A) or as a substitute for an earlier evolved corresponding N-terminal signal (IP3K-B and IP3K-C). In higher vertebrates, and in particular in primates, re-export of nuclear IP3K activity may be guaranteed by the mechanism discovered.